Jin S, Lee MY. The ameliorative effect of hemp seed hexane extracts on the Propionibacterium acnes-induced inflammation and lipogenesis in sebocytes. PLoS One. 2018;13(8):e0202933. View abstract.
Rezapour-Firouzi S, Arefhosseini SR, Ebrahimi-Mamaghani M, et al. Activity of liver enzymes in multiple sclerosis patients with Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention. Complement Ther Med. 2014;22(6):986-93. View abstract.
Citti C, Linciano P, Panseri S, et al. Cannabinoid profiling of hemp seed oil by liquid chromatography coupled to high-resolution mass spectrometry. Front Plant Sci. 2019;10:120. View abstract.
Mikulcová V, Kaspárková V, Humpolícek P, Bunková L. Formulation, characterization and properties of hemp seed oil and its emulsions. Molecules. 2017;22(5). pii: E700. View abstract.
House JD, Neufeld J, Leson G. Evaluating the quality of protein from hemp seed (Cannabis sativa L.) products through the use of the protein digestibility-corrected amino acid score method. J Agric Food Chem. 2010;58(22):11801-7. View abstract.
Rezapour-Firouzi S, Arefhosseini SR, Mehdi F, et al. Immunomodulatory and therapeutic effects of Hot-natured diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients. Complement Ther Med 2013;21(5):473-80.
Stokes JR, Hartel R, Ford LB, Casale TB. Cannabis (hemp) positive skin tests and respiratory symptoms. Ann Allergy Asthma Immunol. 2000;85(3):238-40. View abstract.
Synthetic chemical compound composed of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology.
Synthetic non-psychotropic cannabinoid that blocks NMDA receptors and COX-2 cytokines and chemokines.
Synthetic chemical that blocks endocannabinoids from being received in the brain, and, as a result, suppresses appetite.
Synthetic, more potent analog of THC metabolite THC-11-oic acid.
Suggested Medical Use
Treatment of memory, weight loss, appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation.
Not approved for use outside of laboratory research as of Nov. 11, 2013.
FDA approved in United States as Schedule I drug for appetite stimulation (1992) and for nausea (1985); moved to Schedule III effective July 2, 1999.